MAPT and Alzheimer disease: Evidence suggested that hyperforin could decrease the hyperphosphorylation of tau and NFTs proteins through activating AKT and inhibiting GSK-3β activity via increasing the phosphorylation of GSK-3β, a major substrate of AKT, exerting protective effects in AD [111].